Long-Term Efficacy and Safety of Anlotinib as a Monotherapy and Combined Therapy for Advanced Sarcoma

OBJECTIVE: To analyze the effectiveness of the long-term (> 12 months) administration of anlotinib as a monotherapy or combined therapy in patients with advanced sarcomas. METHODS: A retrospective analysis was conducted of patients with advanced sarcomas with measurable target lesions since 2018....

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Weitao, Du, Xinhui, Wang, Jiaqiang, Wang, Xin, Zhang, Peng, Niu, Xiaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206457/
https://www.ncbi.nlm.nih.gov/pubmed/35726279
http://dx.doi.org/10.2147/OTT.S365506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206457/
https://www.ncbi.nlm.nih.gov/pubmed/35726279
http://dx.doi.org/10.2147/OTT.S365506

Ejemplares similares